Time To Efficacy and Onset Of Action Of Linezolid

This study has been completed.
Information provided by:
ClinicalTrials.gov Identifier:
First received: September 2, 2005
Last updated: May 9, 2011
Last verified: May 2011
To assess the onset of action of linezolid

Condition Intervention Phase
Gram-Positive Bacterial Infections
Skin and Connective Tissue Diseases
Drug: linezolid
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Time To Efficacy and Onset Of Action Of Linezolid In Skin and Soft Tissue Infections

Resource links provided by NLM:

Further study details as provided by Pfizer:

Primary Outcome Measures:
  • Time to defervescence

Secondary Outcome Measures:
  • Reduction of CRP levels Reduction of leucocyte count

Enrollment: 118
Study Start Date: June 2003
Study Completion Date: June 2005

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • suspected grampositive infection
  • fever > 38 C

Exclusion Criteria:

  • Infections to be treated successfully by surgical procedures
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00147511

Sponsors and Collaborators
Study Director: Pfizer CT.gov Call Center Pfizer
  More Information

No publications provided

Responsible Party: Director, Clinical Trial Disclosure Group, Pfizer
ClinicalTrials.gov Identifier: NCT00147511     History of Changes
Other Study ID Numbers: OXAA-0026-162 
Study First Received: September 2, 2005
Last Updated: May 9, 2011
Health Authority: Germany: Federal Institute for Drugs and Medical Devices

Additional relevant MeSH terms:
Bacterial Infections
Connective Tissue Diseases
Gram-Positive Bacterial Infections
Anti-Infective Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Protein Synthesis Inhibitors
Therapeutic Uses

ClinicalTrials.gov processed this record on February 08, 2016